Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor Is Feasible Without Ex Vivo-T Cell Depletion after Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1, 2009, Pages 61-72

  Lee, Kyoo Hyung ^a   Lee, Je Hwan ^a   Lee, Jung Hee ^a   Kim, Dae Young ^a   Kim, Se Hyung ^a   Shin, Ho Jin ^b   Lee, Young Shin ^a   Kang, Young Ah ^a   Seol, Miee ^a   Ryu, Sung Gil ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Antithymocyte globulin; HLA mismatched hematopoietic cell transplantation; Reduced intensity conditioning

Indexed keywords

ANTIINFECTIVE AGENT; ASPARAGINASE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; OXYMETHOLONE; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENGRAFTMENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN CELL; LEUKAPHERESIS; LIVING DONOR; MALE; MORTALITY; MOTHER; MYELODYSPLASTIC SYNDROME; MYOSITIS; PROGENY; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SIBLING; STEM CELL MOBILIZATION; SURVIVAL RATE; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; FAMILY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 58149302659     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.10.025     Document Type: Article

References (35)

1. Martin P.J. Overview of hematopoietic cell transplantation immunology. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation. 3rd ed (2004), Blackwell Publishing, Malden, MA 16-30
2. Barker J.N., Krepski T.P., DeFor T.E., Davies S.M., Wagner J.E., and Weisdorf D.J. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 8 (2002) 257-260
3. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
4. Koh L.P., Rizzieri D.A., and Chao N.J. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 13 (2007) 1249-1267
5. Powles R.L., Morgenstern G.R., Kay H.E., et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1 (1983) 612-615
6. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313 (1985) 765-771
7. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89 (1997) 3864-3872
8. Lacerda J.F., Martins C., Carmo J.A., et al. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. Biol Blood Marrow Transplant 9 (2003) 633-642
9. Guinan E.C., Boussiotis V.A., Neuberg D., et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340 (1999) 1704-1714
10. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
11. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107 (2006) 3065-3073
12. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38 (2006) 291-297
13. Kanda Y., Oshima K., Asano-Mori Y., et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79 (2005) 1351-1357
14. Chen H.R., Ji S.Q., Wang H.X., et al. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 31 (2003) 1019-1025
15. Ichinohe T., Uchiyama T., Shimazaki C., et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 104 (2004) 3821-3828
16. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
17. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
18. Lee K.H., Lee J.H., Kim W.K., Chi H.S., and Lee J.S. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation. Haematologica 86 (2001) 999-1001
19. Cina R.A., Wikiel K.J., Lee P.W., et al. Stable multilineage chimerism without graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation. Transplantation 81 (2006) 1677-1685
20. Fukuda T., Kerbauy F.R., Gooley T., Santos E.B., Storb R., and Sandmaier B.M. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model. Transplantation 82 (2006) 332-339
21. Vanclee A., Lutgens L.C., Oving E.B., et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant 36 (2005) 907-915
22. Fischer A., Durandy A., de Villartay J.P., et al. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine. Blood 67 (1986) 444-449
23. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 91 (1998) 3646-3653
24. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353 (1999) 1755-1759
25. Spitzer T.R., McAfee S.L., Dey B.R., et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75 (2003) 1748-1751
26. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8 (2002) 377-386
27. Tamaki H., Ikegame K., Kawakami M., et al. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 17 (2003) 2052-2054
28. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 12 (2006) 1073-1084
29. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25 (2007) 690-697
30. Sullivan K. Graft-vs.-host disease. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation. 3rd ed (2004), Blackwell Publishing, Malden, MA 635-664
31. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005) 945-956
32. Klein J.P., and Moeschberger M.L. Survival analysis. Techniques of Censored and Truncated Data. 2nd ed. (2003), Springer-Verlag, New York
33. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 353 (2005) 1321-1331
34. Aizawa S., and Sado T. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 52 (1991) 885-889
35. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057